Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes

被引：83

作者：

Nardin, EH

Oliveira, GA

Calvo-Calle, JM

Wetzel, K

Maier, C

Birkett, AJ

Sarpotdar, P

Corado, ML

Thornton, GB

Schmidt, A

机构：

[1] NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10010 USA

[2] Apovia AG, Martinsried, Germany

[3] Apovia Inc, San Diego, CA USA

[4] Adv Biol LLC, New Hope, PA USA

来源：

INFECTION AND IMMUNITY | 2004年 / 72卷 / 11期

关键词：

D O I：

10.1128/IAI.72.11.6519-6527.2004

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report the first phase I trial to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), composed of a modified hepatitis B virus core protein (HBc) containing minimal epitopes of the Plasmodium falciparum circumsporozoite (CS) protein. When expressed in Escherichia coli, the recombinant ICC-1132 protein forms virus-like particles that were found to be highly immunogenic in preclinical studies of mice and monkeys. Twenty healthy adult volunteers received a 20- or a 50-Rg dose of alum-adsorbed ICC-1132 administered intramuscularly at 0, 2, and 6 months. The majority of volunteers in the group receiving the 50-Rg dose developed antibodies to CS repeats as well as to HBc. Malaria-specific T cells that secreted gamma interferon were also detected after a single immunization with ICC-1132-alum. These studies support ICC-1132 as a promising malaria vaccine candidate for further clinical testing using more-potent adjuvant formulations and confirm the potential of modified HBc virus-like particles as a delivery platform for vaccines against other human pathogens.

引用

页码：6519 / 6527

页数：9

共 48 条

[1] IMMUNOGENICITY OF SYNTHETIC PEPTIDES FROM CIRCUMSPOROZOITE PROTEIN OF PLASMODIUM-FALCIPARUM [J].

BALLOU, WR ;

ROTHBARD, J ;

WIRTZ, RA ;

GORDON, DM ;

WILLIAMS, JS ;

GORE, RW ;

SCHNEIDER, I ;

HOLLINGDALE, MR ;

BEAUDOIN, RL ;

MALOY, WL ;

MILLER, LH ;

HOCKMEYER, WT .

SCIENCE, 1985, 228 (4702) :996-999

[2]

BALLOU WR, 1987, LANCET, V1, P1277

[3] A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts [J].

Birkett, A ;

Lyons, K ;

Schmidt, A ;

Boyd, D ;

Oliveira, GA ;

Siddique, A ;

Nussenzweig, R ;

Calvo-Calle, JM ;

Nardin, E .

INFECTION AND IMMUNITY, 2002, 70 (12) :6860-6870

[4]

Birkett A., 2001, Am. J. Trop. Med. Hyg, V65, P258

[5] Efficacy of RTS,S/ASO2 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia:: a randomised trial [J].

Bojang, KA ;

Milligan, PJM ;

Pinder, M ;

Vigneron, L ;

Alloueche, A ;

Kester, KE ;

Ballou, WR ;

Conway, DJ ;

Reece, WHH ;

Gothard, P ;

Yamuah, L ;

Delchambre, M ;

Voss, G ;

Greenwood, BM ;

Hill, A ;

McAdam, KPWJ ;

Tornieporth, N ;

Cohen, JD ;

Doherty, T .

LANCET, 2001, 358 (9297) :1927-1934

[6] Determination of the fold of the core protein of hepatitis B virus ky electron cryomicroscopy [J].

Bottcher, B ;

Wynne, SA ;

Crowther, RA .

NATURE, 1997, 386 (6620) :88-91

[7]

CalvoCalle JM, 1997, J IMMUNOL, V159, P1362

[8]

CALVOCALLE JM, 1992, J IMMUNOL, V149, P2695

[9] CD4+ T-cell- and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein [J].

Charoenvit, Y ;

Majam, VF ;

Corradin, G ;

Sacci, JB ;

Wang, RB ;

Doolan, DL ;

Jones, TR ;

Abot, E ;

Patarroyo, ME ;

Guzman, F ;

Hoffman, SL .

INFECTION AND IMMUNITY, 1999, 67 (11) :5604-5614

[10]

CLYDE DF, 1990, B WORLD HEALTH ORGAN, V68, P9

← 1 2 3 4 5 →